Can a Twice-Yearly PrEP Injection Curb the HIV Pandemic?
Join us for an in-depth discussion on Lenacapavir, a groundbreaking long-acting injectable PrEP formulation administered just twice a year. This session will examine its potential to transform HIV prevention on a global scale, looking at the latest clinical evidence, regulatory pathways, and the access barriers that may shape its rollout, especially in low-resource settings.
The program will feature a special keynote address followed by a panel discussion with leading experts in HIV prevention and global health, exploring how innovation, policy, and equity intersect in the next frontier of HIV response.
Date: November 12, 2025
Location: 120 F St NW, Washington, DC 20001, Gewirz 12th Floor
Time: 1:20 – 3:20 p.m.
Keynote Session
Speaker:
- Moupali Das, MD, MPH, Vice President, Clinical Development, HIV Prevention and Virology Pediatrics, Gilead Sciences
Moderator: Dr. Charles B. Holmes, Director, Georgetown University Center for Innovation in Global Health; Distinguished Scholar and Program Director·O'Neill Institute for National and Global Health Law at Georgetown University Law Center
Panel Discussion
Speakers:
- Micheal Ighodaro, Executive Director, Global Black Gay Men Connect (GBGMC)
- Rupa Patel, MD, MPH, Physician, Whitman-Walker Health
- Mitchell Warren, Executive Director, AIDS Vaccine Advocacy Coalition (AVAC)
Moderator: Martha Sichone Cameron, PhD Candidate, Global Infectious Disease, Georgetown University
DISCLAIMER: The Center for HIV and Infectious Disease Policy receives support from Gilead Sciences, Merck, and ViiV Healthcare. Dr. Holmes receives grant support from the Gates Foundation and serves as an advisor at the Gates Medical Research Institute.
Please contact oneillcomms@georgetown.edu if you have any questions.
